enGene (NASDAQ:ENGN – Get Free Report) and iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.
Earnings and Valuation
This table compares enGene and iTeos Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| enGene | N/A | N/A | -$55.14 million | ($0.58) | -10.36 |
| iTeos Therapeutics | $35.00 million | 7.58 | -$112.64 million | ($3.15) | -2.30 |
enGene has higher earnings, but lower revenue than iTeos Therapeutics. enGene is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| enGene | N/A | -16.69% | -14.27% |
| iTeos Therapeutics | N/A | -20.11% | -17.50% |
Volatility and Risk
enGene has a beta of -0.65, meaning that its share price is 165% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for enGene and iTeos Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| enGene | 0 | 1 | 8 | 1 | 3.00 |
| iTeos Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
enGene presently has a consensus price target of $25.89, indicating a potential upside of 330.76%. iTeos Therapeutics has a consensus price target of $22.25, indicating a potential upside of 206.47%. Given enGene’s higher possible upside, analysts clearly believe enGene is more favorable than iTeos Therapeutics.
Institutional and Insider Ownership
64.2% of enGene shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 13.7% of enGene shares are owned by company insiders. Comparatively, 12.5% of iTeos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
enGene beats iTeos Therapeutics on 8 of the 12 factors compared between the two stocks.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
About iTeos Therapeutics
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
